Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust ...

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.

Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second ...

Scientists develop new blood test to identify individuals at high risk of developing hypertrophic cardiomyopathy, most common ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...

Hypertrophic cardiomyopathy (HCM) is an underdiagnosed genetic heart condition. Raising awareness through advocacy can help increase the rates of diagnosis and proper management. HCM is when the left ...

Future Cardiol. 2013;9(5):697-709. It is extremely important to detect the presence and severity of LVOT obstruction from physical examination, as well as 2D and Doppler echocardiography. The LVOT ...

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...